2023
Multiscale genetic architecture of donor-recipient differences reveals intronic LIMS1 mismatches associated with kidney transplant survival
Sun Z, Zhang Z, Banu K, Gibson I, Colvin R, Yi Z, Zhang W, De Kumar B, Reghuvaran A, Pell J, Manes T, Djamali A, Gallon L, O'Connell P, He J, Pober J, Heeger P, Menon M. Multiscale genetic architecture of donor-recipient differences reveals intronic LIMS1 mismatches associated with kidney transplant survival. Journal Of Clinical Investigation 2023, 133: e170420. PMID: 37676733, PMCID: PMC10617779, DOI: 10.1172/jci170420.Peer-Reviewed Original ResearchConceptsDeath-censored graft lossHuman leukocyte antigenExpression quantitative trait lociT cellsTGF-β1TGF-β1/Smad pathwayDonor-recipient differencesKidney allograft lossChronic allograft rejectionKidney transplant survivalDonor-recipient mismatchActive TGF-β1Allograft lossGraft lossAllograft rejectionTransplant cohortPeripheral bloodLeukocyte antigenClinical trialsImmune cellsHaplotype mismatchGenome-wide scaleTransplant survivalQuantitative trait lociSingle nucleotide polymorphism dataMetabolic reprogramming by immune-responsive gene 1 up-regulation improves donor heart preservation and function
Lei I, Huang W, Noly P, Naik S, Ghali M, Liu L, Pagani F, Abou El Ela A, Pober J, Pitt B, Platt J, Cascalho M, Wang Z, Chen Y, Mortensen R, Tang P. Metabolic reprogramming by immune-responsive gene 1 up-regulation improves donor heart preservation and function. Science Translational Medicine 2023, 15: eade3782. PMID: 36753565, PMCID: PMC10068866, DOI: 10.1126/scitranslmed.ade3782.Peer-Reviewed Original ResearchConceptsImmune response gene 1Primary graft dysfunctionDonor heart preservationValproic acidDonor heartsVPA treatmentHeart preservationHeart functionImmune-responsive gene 1Donor heart functionHistone deacetylase inhibitor valproic acidImproved heart functionAntioxidant protein expressionMetabolic reprogrammingDonor-recipient matchingPromising therapeutic strategyHuman donor heartsInhibitor valproic acidGene 1Graft dysfunctionCardioprotective effectsKetoglutarate solutionTherapeutic strategiesResponse gene-1Nuclear factor
2022
Wanted: An endothelial cell targeting atlas for nanotherapeutic delivery in allograft organs
Liburd ST, Shi AA, Pober JS, Tietjen GT. Wanted: An endothelial cell targeting atlas for nanotherapeutic delivery in allograft organs. American Journal Of Transplantation 2022, 22: 1754-1759. PMID: 35373446, PMCID: PMC9651180, DOI: 10.1111/ajt.17050.Peer-Reviewed Original ResearchConceptsNormothermic machine perfusionEndothelial cellsGraft vasculaturePoor outcomePreservation injuryMachine perfusionProfound shortageOrgan assessmentTransplant therapeuticsDonor comorbiditiesAllograft organClinical useOrgansAttractive targetNanotherapeutic deliveryTherapeutic vehiclesCellsTherapeutic deliveryDeliveryComorbiditiesTransplantGraftInjuryPerfusionVasculature
2021
Differential inflammatory responses of the native left and right ventricle associated with donor heart preservation
Lei I, Huang W, Ward PA, Pober JS, Tellides G, Ailawadi G, Pagani FD, Landstrom AP, Wang Z, Mortensen RM, Cascalho M, Platt J, Chen Y, Lam HYK, Tang PC. Differential inflammatory responses of the native left and right ventricle associated with donor heart preservation. Physiological Reports 2021, 9: e15004. PMID: 34435466, PMCID: PMC8387788, DOI: 10.14814/phy2.15004.Peer-Reviewed Original ResearchConceptsRight ventricleCold ischemiaIL-10Inflammatory responseIL-6 protein levelsCold ischemic preservationEx vivo ischemiaLeft ventricle dysfunctionCold ischemic timeDonor heart preservationInflammatory cytokine expressionCell deathDifferential inflammatory responseTumor necrosis factorComparable inflammatory responsesHuman donor heartsCaspase-3 expressionIschemic preservationVentricle dysfunctionInflammasome expressionIschemic timeRNA sequencingContractile dysfunctionDonor heartsWarm perfusion
2016
Eculizumab Therapy for Chronic Antibody‐Mediated Injury in Kidney Transplant Recipients: A Pilot Randomized Controlled Trial
Kulkarni S, Kirkiles‐Smith N, Deng YH, Formica RN, Moeckel G, Broecker V, Bow L, Tomlin R, Pober JS. Eculizumab Therapy for Chronic Antibody‐Mediated Injury in Kidney Transplant Recipients: A Pilot Randomized Controlled Trial. American Journal Of Transplantation 2016, 17: 682-691. PMID: 27501352, DOI: 10.1111/ajt.14001.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAntibodies, Monoclonal, HumanizedChronic DiseaseComplement C5Complement Inactivating AgentsEarly Intervention, EducationalFemaleFollow-Up StudiesGlomerular Filtration RateGraft RejectionGraft SurvivalHumansIsoantibodiesKidney Failure, ChronicKidney Function TestsKidney TransplantationLiving DonorsMaleMiddle AgedPilot ProjectsPrognosisRisk FactorsTissue DonorsTransplant RecipientsYoung AdultConceptsDe novo donor-specific antibodiesComplement inhibitionTreatment groupsNovo donor-specific antibodiesAntibody-Mediated InjuryC1q-positive patientsDonor-specific antibodiesKidney transplant recipientsPrimary end pointEndothelial cell injuryMo of observationEculizumab therapyEculizumab treatmentHumoral injuryTransplant recipientsKidney transplantRenal functionKidney functionChronic settingEGFR trajectoriesTreatment periodCell injuryPatientsEnd pointPercentage change